This post was originally published on this site People with high blood pressure, or hypertension, during midlife are at a greater risk of developing dementia, irrespective of their blood pressure later on, a long-term follow-up study suggests. The study, “Association of Midlife to Late-Life Blood Pressure Patterns With Incident Dementia,” was published in the Journal…
About Alzheimer’s Disease
Walking into a room and forgetting why you went into the room is normal. Walking into a room and forgetting what room you are in is not normal. Alzheimer’s disease is the most common form of dementia and affects one in ten people over the age of 65. Unfortunately, the exact cause of Alzheimer’s disease is not fully understood however leading scientific experts in the field attribute the illness to the irreversible and progressive generalized degeneration of the brain. Alzheimer’s disease goes well beyond the forgetfulness that may accompany aging, and typically first signs include difficulty remembering current information or performing new tasks. Ongoing hallmark symptoms include impaired memory function, difficulty performing everyday tasks, and neurobehavioral abnormalities. Currently, there is no known cure for Alzheimer’s disease, and multi-disciplinary treatment focuses on symptom management and limiting progression.
Conditions
Alzheimer’s News
Caregiving Tasks Fluctuate between Urgent and Necessary
This post was originally published on this site One of the greatest privileges of my life was to care for my mother, who had Alzheimer’s disease. However, I was constantly fighting an internal battle. A feeling of inadequacy always bubbled beneath the surface. Many caregivers fight similar battles. This is why I wrote the following,…
Protein Treatment, GRF6019, Seen to Help Maintain Cognition in Alzheimer’s Patients in Phase 2 Trial
This post was originally published on this site Alkahest’s experimental blood-derived protein GRF6019 helps maintain cognition and function in mild to moderate Alzheimer’s disease patients, results of a six-month Phase 2 clinical trial show. “These top-line results indicate a potential benefit of this plasma protein fraction in slowing the progression of cognitive decline in patients with…
Blood Markers May ID People Most Likely to Gain Cognitively with Aerobic Exercise, Study Reports
This post was originally published on this site Blood levels of certain molecules— metabolites and amino acids — may help to identify people with Alzheimer’s disease who are more likely to improve their cognitive skills in response to aerobic exercise, a study suggests. These results were shared in the poster “Plasma Metabolites to Predict Response to Exercise…
AC Immune’s Anti-Tau Vaccine ACI-35.030 to Be Tested in Phase 1b/2a Trial
This post was originally published on this site AC Immune is launching a Phase 1b/2a clinical trial to evaluate an investigational anti-tau vaccine called ACI-35.030 as a potential disease-modifying treatment for Alzheimer’s disease and other disorders characterized by the accumulation of tau protein. The presence of abnormal aggregates of beta-amyloid and tau proteins in the brain…
Self-talk Your Way to a Positive Outlook
This post was originally published on this site Have you heard the saying, “Talking to yourself is OK as long as you don’t expect a response”? Most of us do it, and I believe that self-talk is particularly prevalent among caregivers. I am an audible self-talker, whispering declarations and questions to no one in particular.…
UAFS, Arkansas Senior Residence Use 3D Technology to Aid Recreational Therapy
This post was originally published on this site To foster the cognitive stimulation of its Alzheimer’s disease (AD) residents, an Arkansas senior living center collaborated with the University of Arkansas – Fort Smith (UAFS) to produce recreational 3D-printed items. A set of large-scale, lightweight, and colorful plastic nuts and bolts were made especially for those Methodist…
AZTherapies Completes Enrollment for ALZT-OP1 Trial for Early Alzheimer’s
This post was originally published on this site AZTherapies has completed enrollment for its Phase 3 COGNITE trial, testing the safety and efficacy of its investigational ALZT-OP1 for the treatment of early Alzheimer’s disease (AD). A total of 620 participants were enrolled following the screening of 1,800 patients, the company said. “With the COGNITE trial…
Chemical Compound Can Restore Neural Function in Familial Alzheimer’s, Study Finds
This post was originally published on this site A mutation in a gene linked to familial Alzheimer’s disease promotes the disease by reducing the points of contact between nerve cells and impairing neuronal communication, a study has found. A chemical compound, called EVP4593, partially rescued the mutation’s negative effects, suggesting it may hold a…
Maintaining Friendships Is Challenging for Caregivers and Those with Alzheimer’s
This post was originally published on this site This week people around the world celebrated International Day of Friendship. In 2011, the United Nations General Assembly designated July 30 as a day to recognize the power of friendship to address disharmony in the world by “accumulating bonds of camaraderie and developing strong ties of trust.”…
$47M Federal Grant Adds Brain Imaging to Pivotal Lifestyle Interventions Study
This post was originally published on this site The University of California, Berkeley (UC Berkeley) will receive an expected $47 million in a federal grant that will add advanced brain imaging to a pivotal study to determine whether lifestyle modifications can protect memory in those at risk of developing dementia. With the five-year grant from…
Longeveron Gets $3M Alzheimer’s Association Grant to Continue Stem Cell Study
This post was originally published on this site Biopharmaceutical company Longeveron will use a $3 million Alzheimer’s Association grant to advance innovative research that uses adult stem cells to target neuroinflammation in people with mild Alzheimer’s disease (AD). Funding is through the organization’s Part the Cloud global research grant program, designed to find promising targets for…